Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

A premarket piece for developer adherence gives providers peace of mind about the safety of the products they're using and a ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.66 which represents a slight increase of $0.53 or 3.09% from the prior close of $17.13. The stock opened at $17.55 and ...

Anticipating a 35% CAGR in 2025, Hims & Hers is poised for substantial growth. Read why I maintain my strong buy rating on ...

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 9 unusual trades. Delving into the details ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 39 unusual trades. Delving into the details ...

Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after ...